182 related articles for article (PubMed ID: 1783991)
1. A kinetic-dynamic model to explain the relationship between high potency and slow onset time for neuromuscular blocking drugs.
Donati F; Meistelman C
J Pharmacokinet Biopharm; 1991 Oct; 19(5):537-52. PubMed ID: 1783991
[TBL] [Abstract][Full Text] [Related]
2. Simulation of the kinetics of neuromuscular block: implications for speed of onset.
Dilger JP
Anesth Analg; 2013 Oct; 117(4):792-802. PubMed ID: 23456666
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic/Pharmacodynamic Model of CW002, an Investigational Intermediate Neuromuscular Blocking Agent, in Healthy Volunteers.
Kaullen JD; Owen JS; Brouwer KLR; Heerdt PM; Lien CA; Savarese JJ; Schmith VD
Anesthesiology; 2018 Jun; 128(6):1107-1116. PubMed ID: 29494403
[TBL] [Abstract][Full Text] [Related]
4. An extended pharmacokinetic/pharmacodynamic model describing quantitatively the influence of plasma protein binding, tissue binding, and receptor binding on the potency and time course of action of drugs.
Proost JH; Wierda JM; Meijer DK
J Pharmacokinet Biopharm; 1996 Feb; 24(1):45-77. PubMed ID: 8827583
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in neuromuscular blocking agents.
Bartkowski RR
Am J Health Syst Pharm; 1999 Jun; 56(11 Suppl 1):S14-7. PubMed ID: 10437712
[TBL] [Abstract][Full Text] [Related]
6. Onset of the neuromuscular block simulated in an anatomical model.
Nigrovic V; Banoub A; Diefenbach C; Mellinghoff H; Buzello W
Br J Clin Pharmacol; 1997 Jan; 43(1):55-63. PubMed ID: 9056053
[TBL] [Abstract][Full Text] [Related]
7. An analytical pharmacodynamic model for nondepolarizing neuromuscular blocking agents.
d'Hollander A; Delcroix C
J Pharmacokinet Biopharm; 1981 Feb; 9(1):27-40. PubMed ID: 6453216
[TBL] [Abstract][Full Text] [Related]
8. Neuromuscular blocking drugs: onset and intubation.
Bevan DR
J Clin Anesth; 1997 Sep; 9(6 Suppl):36S-39S. PubMed ID: 9278854
[TBL] [Abstract][Full Text] [Related]
9. Relationship between train-of-four ratio and first-twitch depression during neuromuscular blockade: a pharmacokinetic/dynamic explanation.
Bartkowski RR; Epstein RH
J Pharmacokinet Biopharm; 1990 Aug; 18(4):335-46. PubMed ID: 2231323
[TBL] [Abstract][Full Text] [Related]
10. Vecuronium induced neuromuscular blockade. The effect of increasing dose on speed of onset.
Casson WR; Jones RM
Anaesthesia; 1986 Apr; 41(4):354-7. PubMed ID: 2871770
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the neuromuscular blocking effect of cisatracurium and atracurium on the larynx and the adductor pollicis.
Kirov K; Motamed C; Decailliot F; Behforouz N; Duvaldestin P
Acta Anaesthesiol Scand; 2004 May; 48(5):577-81. PubMed ID: 15101851
[TBL] [Abstract][Full Text] [Related]
12. Newer neuromuscular blocking agents: how do they compare with established agents?
Sparr HJ; Beaufort TM; Fuchs-Buder T
Drugs; 2001; 61(7):919-42. PubMed ID: 11434449
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Pharmacology in the Rhesus Monkey of CW 1759-50, a New Ultra-short Acting Nondepolarizing Neuromuscular Blocking Agent, Degraded and Antagonized by L-Cysteine.
Savarese JJ; Sunaga H; McGilvra JD; Belmont MR; Murrell MT; Jeannotte E; Cooke FE; Wastila WB; Heerdt PM
Anesthesiology; 2018 Nov; 129(5):970-988. PubMed ID: 30212413
[TBL] [Abstract][Full Text] [Related]
14. Comparative clinical pharmacology of rocuronium, cisatracurium, and their combination.
Naguib M; Samarkandi AH; Ammar A; Elfaqih SR; Al-Zahrani S; Turkistani A
Anesthesiology; 1998 Nov; 89(5):1116-24. PubMed ID: 9821999
[TBL] [Abstract][Full Text] [Related]
15. Fazadinium and pancuronium: a pharmacodynamic study.
Hull CJ; English MJ; Sibbald A
Br J Anaesth; 1980 Dec; 52(12):1209-21. PubMed ID: 6108777
[TBL] [Abstract][Full Text] [Related]
16. Dose-response and Cardiopulmonary Side Effects of the Novel Neuromuscular-blocking Drug CW002 in Man.
Heerdt PM; Sunaga H; Owen JS; Murrell MT; Malhotra JK; Godfrey D; Steinkamp M; Savard P; Savarese JJ; Lien CA
Anesthesiology; 2016 Dec; 125(6):1136-1143. PubMed ID: 27749289
[TBL] [Abstract][Full Text] [Related]
17. Physicochemical properties of neuromuscular blocking agents and their impact on the pharmacokinetic-pharmacodynamic relationship.
Roy JJ; Varin F
Br J Anaesth; 2004 Aug; 93(2):241-8. PubMed ID: 15169739
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics and cardiopulmonary side effects of CW002, a cysteine-reversible neuromuscular blocking drug in dogs.
Heerdt PM; Malhotra JK; Pan BY; Sunaga H; Savarese JJ
Anesthesiology; 2010 Apr; 112(4):910-6. PubMed ID: 20234311
[TBL] [Abstract][Full Text] [Related]
19. Development and potential clinical impairment of ultra-short-acting neuromuscular blocking agents.
Lien CA
Br J Anaesth; 2011 Dec; 107 Suppl 1():i60-71. PubMed ID: 22156271
[TBL] [Abstract][Full Text] [Related]
20. Is time to peak effect of neuromuscular blocking agents dependent on dose? Testing the concept of buffered diffusion.
Proost JH; Houwertjes MC; Wierda JM
Eur J Anaesthesiol; 2008 Jul; 25(7):572-80. PubMed ID: 18400136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
